Back
65· Active
Health & Science2d 7h ago
The FDA granted Orphan Drug Designation to a personalized mRNA vaccine candidate designed to treat resected pancreatic ductal adenocarcinoma.
Silver Spring, Maryland, USA
Who
U.S. Food and Drug Administration (FDA) and BioNTech
What
The FDA granted Orphan Drug Designation to a personalized mRNA vaccine candidate designed to treat resected pancreatic ductal adenocarcinoma.
When
Sun, 07 Jun 2026 02:30:05 GMT · 2d 7h ago
Where
Silver Spring, Maryland, USA · 39.030N, 77.030W
Why
The designation follows high-level data from a Phase I trial showing that the vaccine induced significant T-cell responses in 50% of treated patients.
The Frontline Impact
How this affects you
This accelerates the development and review process for a treatment in a high-mortality cancer field, signaling potential breakthroughs in tailor-made immunotherapy.
Story chain
1 event in this threadNo related history yet — this is the origin event.
Verified Sources & Citations
Credibility ratings reflect the AI ingestion pipeline's assessment of source provenance.